AbbVie Inc.
Every calculator, already run for ABBV
Open the full toolkit →You have the numbers on ABBV. Get the argument.
A written report on which of these readings actually decide the outcome for AbbVie Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
31 analysts covering ABBVAnalyst Price Target Disagreement for AbbVie Inc.
Wall Street's bull case implies +28% from the current price; the bear case implies -22%. A 50% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for ABBV
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About AbbVie Inc.
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Ju…
ABBV — frequently asked
Is ABBV a buy right now?
Wall Street's consensus rating on AbbVie Inc. is Buy across 31 analysts, with a mean price target of $277.31 (+8% vs. the current $257.12). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is ABBV overvalued?
ABBV trades at 72.4x trailing earnings, against a DCF fair value of $371 per share. The current price implies 2% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is ABBV's next earnings date?
AbbVie Inc. is next scheduled to report earnings around Oct 29, 2026. A full ABBV research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for AbbVie Inc.?
Analysts covering AbbVie Inc. (ABBV) range from a bear-case target of $200.00 to a bull-case high of $328.00, with a mean consensus target of $277.31 across 29 analysts. The spread of $128.00 (50% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare AbbVie Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For AbbVie Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full ABBV research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on AbbVie Inc., in minutes. 3 free reports included with every account — no credit card required.